Article Text

PDF
Inhibitory effect of rapamycin and dexamethasone on production of IL-17 and IFN-γ in Vogt–Koyanagi–Harada patients
  1. K Yang1,2,
  2. J Wen1,
  3. X Liu2,
  4. A Kijlstra3,4,
  5. L Chen2,
  6. W Chi2,
  7. H Zhou2,
  8. X Huang2,
  9. P Yang2,5
  1. 1
    The First Clinical Hospital of ZhengZhou University, ZhengZhou, PR China
  2. 2
    State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Zhongshan, PR China
  3. 3
    Eye Research Institute Maastricht, Department of Ophthalmology, University Hospital Maastricht, Maastricht, The Netherlands
  4. 4
    Animal Sciences Group, Wageningen University, Lelystad, The Netherlands
  5. 5
    The First Affiliated Hospital, Chongqing Medical University, Chongqing, PR China
  1. Professor P Yang, Zhongshan Ophthalmic Center, Sun Yat-sen University, 54 South Xianlie Road, Guangzhou, 510060, PR China; peizengy{at}126.com

Abstract

Aims: To evaluate the effect of rapamycin (RAPA) and dexamethasone (DEX) on the production of IL-17 and IFN-γ by peripheral blood mononuclear cells (PBMCs) from Vogt–Koyanagi–Harada (VKH) patients and healthy individuals.

Methods: Blood samples were drawn from 10 active VKH patients and 10 healthy individuals. PBMCs were cultured with or without anti-CD3 and anti-CD28 antibodies in the presence or absence of different concentrations of RAPA or DEX for 72 h. IL-17 and IFN-γ concentrations in the supernatants were measured by enzyme-linked immunosorbent assay (ELISA).

Results: The expression of IL-17 and IFN-γ was significantly increased in active VKH patients compared with that in healthy controls. Both RAPA and DEX were able to significantly inhibit the production of IL-17 and IFN-γ by PBMCs from patients and healthy controls. RAPA was able to completely inhibit IL-17 production at a dosage of 10 ng/ml but only partially suppressed IFN-γ production even at a much higher concentration (1000 ng/ml). DEX inhibited the production of both IL-17 and IFN-γ by approximately 70%.

Conclusions: This study indicates that both RAPA and DEX inhibit the production of IL-17 and IFN-γ by PBMCs. RAPA is much stronger in inhibiting the production of IL-17 than DEX.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

  • Ethics approval: Ethics approval was provided by the Clinical Ethical Research Committee of Zhongshan Ophthalmic Center.

  • Patient consent: Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.